Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen(®)

BACKGROUND: Filgrastim or methionyl-granulocyte colony-stimulating factor (Met-G-CSF), is a recombinant therapeutic protein widely used to treat severe neutropenia caused by myelosuppressive drugs in patients with nonmyeloid malignancies. In addition to its role in the regulation of granulopoiesis,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Crobu, Davide, Spinetti, Gaia, Schrepfer, Rodolfo, Tonon, Giancarlo, Jotti, Gloria Saccani, Onali, Pierluigi, Dedoni, Simona, Orsini, Gaetano, Di Stefano, Andrea
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2014
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3942296/
https://ncbi.nlm.nih.gov/pubmed/24555723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-6511-15-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi